Bionomics appoints chief business officer

Biopharma company Bionomics (ASX:BNO) has announced the appointment of Tony Colasin as its chief business officer. Based in San Diego, California, Colasin will lead corporate development for the company, including business development and strategic opportunities.

Colasin joins Bionomics from Ironwood Pharmaceuticals, where he served as vice president of corporate development and was responsible for strategy and tactical oversight of in-licensing, mergers and acquisitions. He was previously senior director of business development for ICOS Corporation and has also held positions at Amgen in various marketing, corporate finance and corporate development roles.

“We are delighted to welcome Tony to the Bionomics team,” said Bionomics CEO and Managing Director Deborah Rathjen. “His operational experience in our core therapeutic areas [of] CNS and oncology, as well as his ability to execute on business development activities, will be critical as we continue to advance our clinical programs and expand our US presence.”

“I am very much looking forward to working with the Bionomics team to grow the company and its strategic footprint in the US and worldwide,” said Colasin. “I see tremendous opportunity for both our CNS and cancer pipelines, especially our lead programs BNC210 for anxiety and depression and BNC101 targeting cancer stem cells.”

Bionomics (ASX:BNO) shares were trading unchanged at $0.45 as of around 1.30 pm on Monday.